RJA
ZOM

Raymond James & Associates’s Zomedica Corp. ZOM Stock Holding History

Raymond James & Associates’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,110
Closed -$4K – 4370
2021
Q4 		$4K Buy
13,110
+200
+2% +$90 ﹤0.01% 4108
2021
Q3 		$7K Sell
12,910
-2,300
-15% -$1.36K ﹤0.01% 4072
2021
Q2 		$13K Sell
15,210
-2,119
-12% -$1.97K ﹤0.01% 4021
2021
Q1 		$27K Sell
17,329
-3,857
-18% -$6.3K ﹤0.01% 3901
2020
Q4 		$5K Buy
+21,186
New +$2.7K ﹤0.01% 3739

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Raymond James & Associates's ZOM Position: Q1 2022 in Review

Raymond James & Associates sold out of Zomedica Corp. (ZOM) in Q1 2022, closing a stake of 13,110 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in ZOM in Q4 2020 and held it in 5 quarters. The position peaked at $27K in Q1 2021. 110 funds tracked by Wall St. Rank hold ZOM as of Q1 2022.

  • Raymond James & Associates reported no remaining Zomedica Corp. position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 13,110 Zomedica Corp. shares in Q1 2022, an estimated $4K.
  • Raymond James & Associates first reported a position in Zomedica Corp. in Q4 2020 and held it in 5 quarters.
  • Raymond James & Associates's Zomedica Corp. position peaked at $27K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.